390 - Cisplatin, cyclophosphamide, methotrexate, and 5-fluorouracil (PCMF) as first line therapy of metastatic triple negative breast cancer (mTNBC) in pa...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Presenter Dragutin Donat
Authors D.A. Donat
  • Internal Oncology, Institute of Oncology Vojvodina, 21204 - Sremska Kamenica/YU



The purpose of this study was to evaluate the efficacy and toxicity of applied PCMF chemotherapy every four weeks (q4w) in the treatment of MTNBC patients (pts) previously treated with adjuvant anthracyclines and taxanes.


We administered cisplatin 30 mg/m2 on day 1 to 3 with regular hydration, cyclophosphamide 400 mg/m2 on day 1 to 5, 5-fluorouracil 500mg/m2 on day 2 and 4, and methotrexate 30mg/m2 on day 1, 3, and 5.The evaluation was performed after 4 cycles. We included 76 pts (median age 58 years, range: 32-71 years). PS medium was 1 (0-2); 21 pts (27.6%) were premenopausal and 55 (62.4%) postmenopausal. Adjuvant anthracyclines (AC or FAC x 4) and taxanes (paclitaxel/w x 12, or docetaxel/3w x 4) therapy was applied in all patients. DFS <12 months was obtained in 47 patients (61.8%) and >12 months in 29 pts (38.2%). Adjuvant radiotherapy was applied in 48 pts (63.2%). Visceral metastases were observed in 51 pts (67.1%), bone metastases in 34 (44.7%), and soft tissue metastases in 11 pts (14.5%). Only one organ was affected in 15 pts (19.7%), in 41 (53.9%) two organs, and in 5 pts (6.6%) three or more.


We evaluated 76 pts with MTNBC after 4 cycles of PCMF chemotherapy. CR was found in 3 pts (3.9%), PR in 16 pts (21.0%), SD in 11 pts (14.5%), and PD in 39 pts (51.3%); with ORR in 19 pts (24.9%) and TCR in 30 pts (39.5%). Hematological toxicity: grade 3 and 4 anemia was found in 4 pts (5.3%) and leukopenia in 9 pts (11.8%). Non-hematological toxicity: renal grade 3 awas observed in 2 pts (2.6%). Not a single therapy was interrupted due to toxicity, but therapy prolongation was present in 15% of applied cycles.


The application of PCMF chemotherapy q4w in the treatment of patients previously treated with anthracyclines and taxanes as adjuvant treatment appeared to be effective with ORR in 24.9% and TCR in 39.5% and can be administered with good tolerance.It is today our standard treatment in this pts population.


All authors have declared no conflicts of interest.